| Phase 3 |
| NCT06937905 |
Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced… |
Neuroendocrine Carcinoma |
Recruiting |
| NCT07005128 |
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab… |
Small-cell Lung Cancer |
Recruiting |
| NCT05740566 |
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung… |
Small Cell Lung Cancer (SCLC) |
Active, Not Recruiting |
| NCT06117774 |
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung… |
Limited Stage Small Cell Lung Cancer |
Active, Not Recruiting |
| NCT07637513 |
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer |
Limited Stage Small-Cell Lung Cancer |
Not Yet Recruiting |
| Phase 2 |
| NCT07061080 |
Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab |
Advanced Neuroendocrine Carcinomas of The Digestive System |
Recruiting |
| NCT07423585 |
Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer |
Extensive Stage Lung Small Cell Carcinoma |
Recruiting |
| NCT06893783 |
Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine… |
Neuroendocrine Carcinomas (NEC) |
Recruiting |
| NCT07111507 |
A Study of Tarlatamab for People With Prostate Cancer |
Metastatic Prostate Cancer |
Recruiting |
| NCT07242547 |
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage… |
Limited-stage Small-cell Lung Cancer |
Recruiting |
| NCT07203053 |
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer… |
Extensive Stage Lung Small Cell Cancer |
Recruiting |
| NCT06745323 |
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in… |
Small Cell Lung Cancer (SCLC) |
Active, Not Recruiting |
| NCT06502977 |
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer… |
Extensive Stage Small Cell Lung Cancer |
Active, Not Recruiting |
| NCT07402343 |
Tarlatamab for SCLC Brain Metastases |
Small Cell Lung Cancer |
Not Yet Recruiting |
| Phase 1/2 |
| NCT06814496 |
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors |
Melanoma |
Recruiting |
| NCT07243470 |
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors |
Glioma |
Recruiting |
| Phase 1 |
| NCT06551142 |
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) |
Neoplasms |
Recruiting |
| NCT06598306 |
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer… |
Extensive Stage Small Cell Lung Cancer |
Recruiting |
| NCT07037758 |
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage… |
Extensive Stage Small Cell Lung Cancer |
Recruiting |
| NCT07531095 |
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small… |
Small Cell Lung Cancer |
Recruiting |
| NCT05361395 |
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in… |
Extensive Stage Small Cell Lung Cancer |
Active, Not Recruiting |
| NCT06898957 |
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death… |
Small Cell Lung Cancer |
Active, Not Recruiting |